文献速递眼底病与葡萄膜炎

视网膜新生血管对阿柏西普或全视网膜光凝的地形学反应:CLARITY随机临床试验事后分析

Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: Post Hoc Analysis of the CLARITY Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

该事后分析纳入120例初治增殖性糖尿病视网膜病变患者,评估视网膜四个象限内视盘新生血管(NVD)与其他部位新生血管(NVE)的分布及对阿柏西普或全视网膜光凝(PRP)的地形学反应。结果显示NVD较NVE少见但更耐药,阿柏西普对NVE的消退率优于PRP,而两种治疗对NVD均不特别有效。

要点

  • NVD较NVE少见但持续存在率更高、对现有治疗更耐药。
  • 两种治疗对NVD的消退率无显著差异,52周时均不特别有效。

核心结论

  • NVD较NVE少见但更耐药,阿柏西普治疗NVE优于PRP,而两种治疗对NVD均不特别有效,未来需针对NVD开发更有效治疗。

研究设计与样本

  • CLARITY试验(2b期随机、单盲、多中心、非劣效性)的事后分析,纳入120例初治增殖性糖尿病视网膜病变患者,按1:1随机接受阿柏西普或PRP,于基线及治疗后12周、52周行彩色眼底照相评估四个象限NV。

主要发现

  • 基线时NVD伴或不伴NVE占42眼(35.0%),仅NVE占78眼(65.0%),NVE好发于鼻侧象限(64眼[53.3%])。
  • 52周时NVE眼消退率(89/102[87.3%])高于NVD眼(23/43[53.5%]),NVD持续存在率(20/39[51.3%])高于NVE(29/100[29.0%])。
  • NVE中颞侧象限消退率最低(32/42[76.2%])。

临床怎么用

  • 对NVE可优先考虑阿柏西普以获得更高消退率,而NVD对现有治疗反应有限,需密切随访并探索更有效治疗。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Eyes with proliferative diabetic retinopathy have a variable response to treatment with panretinal photocoagulation (PRP) or anti-vascular endothelial growth factor agents. The location of neovascularization (NV) is associated with outcomes (eg, patients with disc NV [NVD] have poorer visual prognosis than those with NV elsewhere [NVE]). OBJECTIVE: To investigate the distribution of NV in patients with proliferative diabetic retinopathy and the topographical response of NV to treatment with aflibercept or PRP. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the phase 2b randomized clinical single-masked multicenter noninferiority Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy (CLARITY) trial was conducted from November 1, 2019, to September 1, 2020, among 120 treatment-naive patients with proliferative diabetic retinopathy to evaluate the topography of NVD and NVE in 4 quadrants of the retina on color fundus photography at baseline and at 12 and 52 weeks after treatment. EXPOSURES: In the CLARITY trial, patients were randomized to receive intravitreal aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks, and as needed from 12 weeks onward) or PRP (completed in initial fractionated sessions and then on an as-needed basis when reviewed every 8 weeks). MAIN OUTCOMES AND MEASURES: Main outcomes were per-retinal quadrant frequencies of NV at baseline and frequencies of patterns of regression, recurrence, and new occurrence at 12-week and 52-week unmasked follow-up. RESULTS: The study included 120 treatment-naive patients (75 men; mean [SD] age, 54.8 [14.6] years) with proliferative diabetic retinopathy (there was a 1:1 ratio of eyes to patients). At baseline, NVD with or without NVE was observed in 42 eyes (35.0%), and NVE only was found in 78 eyes (65.0%); NVE had a predilection for the nasal quadrant (64 [53.3%]). Rates of regression with treatment were higher among eyes with NVE (89 of 102 [87.3%]) compared with eyes with NVD (23 of 43 [53.5%]) by 52 weeks, with NVD being more resistant to either treatment with higher rates of persistence than NVE (20 of 39 [51.3%] vs 29 of 100 [29.0%]). Considering NVE, the regression rate in the temporal quadrant was lowest (32 of 42 [76.2%]). Eyes treated with aflibercept showed higher rates of regression of NVE compared with those treated with PRP (50 of 52 [96.2%] vs 39 of 50 [78.0%]; difference, 18.2% [95% CI, 5.5%-30.8%]; P = .01), but no difference was found for NVD (11 of 17 [64.7%] vs 12 of 26 [46.2%]; difference, 18.6% [95% CI, -11.2% to 48.3%]; P = .23). CONCLUSIONS AND RELEVANCE: This post hoc analysis found that NVD is less frequent but is associated with more resistance to currently available treatments than NVE. Aflibercept was superior to PRP for treating NVE, but neither treatment was particularly effective against NVD by 52 weeks. Future treatments are needed to better target NVD, which has poorer visual prognosis. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN32207582.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Halim S, Nugawela M, Chakravarthy U, et al. Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: Post Hoc Analysis of the CLARITY Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 33704351. doi:10.1001/jamaophthalmol.2021.0108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。